Physician profile

Michael D Haley

Internal Medicine · Reno, NV

NPI 1225112550

$645.55

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$610.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corcept Therapeutics $220.54 2024 Korlym
Lilly USA, LLC $167.33 2023-2024 Mounjaro
Glaxosmithkline, LLC. $125.00 2024 Arexvy
Edwards Lifesciences Corporation $82.71 2023 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Amarin Pharma, INC. $34.68 2019
Boehringer Ingelheim Pharmaceuticals, INC. $15.29 2024 Jardiance

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Haley

$645.55

in general payments reported 2019-2025

Years
2019-2024
Top company
Corcept Therapeutics

https://glasscript.com/doctor/191338/michael-d-haley

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.